BGPT: Author Review: Yu-Quan Wei

Fuel Your Discoveries

Quick Explanation Copied

Yu-Quan (Yuquan) Wei — critical scientific appraisal

Strength signals in the data you provided: very high broad citation impact (OpenAlex snapshot), plus recurring focus in cancer immunology/immunotherapy and delivery/biomaterials themes (from work titles and top works list). Key uncertainty: the dataset here is incomplete (only 22 specific titles shown) and citation metrics are author-name–disambiguation–sensitive (multiple “Wei” variants exist in OpenAlex matches).

Open a deeper BGPT query:

Long Explanation

Author Review: Yu-Quan Wei

Date context: 2026-04-03. Evaluation is based strictly on: (i) the citation-metric snapshot and (ii) the partial list of paper titles you provided.

Critical epistemic note: Author-name disambiguation is a known failure mode in bibliometric systems; your OpenAlex matches include multiple close variants (e.g., “Yuquan Wei” and other “Wei” forms). Treat metrics as author-name-limited until disambiguation is verified.

1) Publication & citation landscape (from your OpenAlex snapshot)

The figure below uses the raw “counts_by_year” array from your provided OpenAlex object (works_count, oa_works_count, cited_by_count per year).

2) Topic emphasis (from provided top works list)

Your snapshot includes top works and their themes. Below I visualize the top-work DOI list you provided and cluster them by topic label inferred from your OpenAlex fields (not from full text).

3) What the paper titles suggest about scientific scope (based on your 22-title list)

From the titles you provided, recurring motifs include: (i) nucleic acid transport/microRNA processing, (ii) cancer immunotherapy approaches (CAR-T / vaccine platforms / armed T cells), (iii) tumor microenvironment and macrophage biology, and (iv) biomaterials/delivery systems.

4) Concrete evidence from named top works (DOIs you provided)

Below are only claims that are supported by the DOIs/titles/years/abstract snippets present in your OpenAlex snapshot. These are used to ground the thematic assessment, not to overgeneralize beyond the evidence supplied.

Evidence quality warning: bibliometric indicators do not measure internal validity, causal inference strength, blinding/randomization, or reproducibility. High citation counts can arise for many reasons (including broad technical utility).

Top work (from snapshot)	Year	Type	Journal	Cited by (snapshot)	Open-access status (snapshot)
Targeting PI3K in cancer: mechanisms and advances in clinical trials	2019	review	Molecular Cancer	1536	gold (snapshot)
Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature	2012	review	PLoS ONE	1025	gold (snapshot)
Targeting TGF-β signal transduction for fibrosis and cancer therapy	2022	review	Molecular Cancer	943	gold (snapshot)
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity	2020	article	Nature	843	bronze (snapshot)
Vaccine adjuvants: mechanisms and platforms	2023	review	Signal Transduction and Targeted Therapy	757	gold (snapshot)

5) Scientific strength assessment (what is plausible vs what is unverified here)

5.1 Likely strengths (based on evidence present)

Cross-domain integration between immunology, oncology, and delivery/biomaterials is consistent with both your 22-title list and the provided top-works DOIs (e.g., PI3K/cancer review and vaccine-adjuvant review).
Engagement with quantitative synthesis is suggested by the presence of an explicit meta-analysis title on tumor-associated macrophages prognostic significance.
Vaccine/immune system relevance is supported by at least one high-profile vaccine immunology research article in the snapshot (RBD-based SARS-CoV-2 vaccine) and by vaccine-adjuvant reviews.

5.2 Major limitations / uncertainties (important)

Name disambiguation risk: your OpenAlex “matches” include multiple closely named entities (e.g., different “Yuquan Wei” ORCIDs and other variants). The bibliometric tallies may partially mix multiple researchers or split one researcher across profiles. (This limitation is inherent to the provided snapshot; verification requires ORCID/affiliation matching.)
Selection bias from titles: your 22-paper list is not the full publication set (and includes a mixture of primary research, reviews, and possibly clinical/prospective items). Title-based categorization can misclassify the real biology studied (e.g., a clinical study title doesn’t guarantee randomized design).
No full-text evidence here: you requested raw experimental grounding, but this author review cannot access full-text raw results in the data you provided. Therefore, causal claims about rigor (controls, blinding, effect sizes, replication, statistical handling) cannot be verified.
Publication bias risk (general): high-citation papers are more likely to represent successful/impactful studies; null results are underrepresented in typical citation-based metrics.
Cross-field citation inflation: immunology/cancer review articles can accrue citations for being broadly referenced regardless of whether a specific experimental claim is correct.

5.3 Evidence-weighted conclusion (confidence-labeled)

Most supported (moderate confidence): The provided record indicates sustained involvement in cancer immunology/immunotherapy themes and vaccine/immunology scholarship (supported by titles + provided top-work DOIs).

Moderately supported: Engagement with synthesis methods (meta-analysis) is suggested by a cited meta-analysis title.

Unverified here (low confidence): Internal scientific rigor of specific experiments (methodological quality, effect sizes, reproducibility) because no full-text raw results were provided in the dataset.

6) How to falsify or substantially change this assessment

If ORCID/disambiguation shows that the majority of the metric footprint belongs to a different “Wei” entity, the bibliometric impact attribution would collapse.
If full-text auditing of representative experimental papers reveals systematic methodological weaknesses (e.g., missing key controls, nonconvergent replicates, inconsistent statistics), then the “moderate confidence” theme-level inference would not translate to high scientific rigor.
If the cancer immunology/vaccine claims in top works are primarily secondary/interpretive reviews without novel experimental contributions, then the evidence for hands-on experimental rigor would decrease.

Important: I can’t complete a true raw-data audit from the material here.

To perform the “raw experimental evidence” review you’re asking for, we must retrieve and inspect full-text experimental results for the author’s papers. The UI button below starts an agent to do that iteratively.

This will iteratively pull full-text evidence and evaluate methodological rigor, reproducibility signals, and effect-direction consistency across representative papers.

Feedback:

Updated: April 03, 2026